Miravirsen

Last updated
Miravirsen
Miravirsen structure.svg
Clinical data
Other namesSPC3649
Routes of
administration 		Intravenous or subcutaneous injection
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
  • RNA, (P-thio)((2'-O,4'-C-methylene)m5C-dC-(2'-O,4'-C-methylene)A-dT-dT-(2'-O,4'-C-methylene)G-(2'-O,4'-C-methylene)m5U-dC-dA-(2'-O,4'-C-methylene)m5C-dA-(2'-O,4'-C-methylene)m5C-dT-(2'-O,4'-C-methylene)m5C-(2'-O,4'-C-methylene)m5C)
CAS Number
PubChem CID
UNII
Chemical and physical data
Formula C151H185N49O83P14S14
Molar mass 4896.87 g·mol−1
  • CC1=CN([C@H]2CC(OP(O)(=S)OC[C@H]3O[C@H](CC3OP(O)(=S)OC[C@@]34COC([C@@H](O3)N3C=NC5=C3N=C(N)NC5=O)C4OP(O)(=S)OC[C@@]34COC([C@@H](O3)N3C=C(C)C(=O)NC3=O)C4OP(O)(=S)OC[C@H]3O[C@H](CC3OP(O)(=S)OC[C@H]3O[C@H](CC3OP(O)(=S)OC[C@@]34COC([C@@H](O3)N3C=CC(N)=NC3=O)C4OP(O)(=S)OC[C@H]3O[C@H](CC3OP(O)(=S)OC[C@@]34COC([C@@H](O3)N3C=CC(N)=NC3=O)C4OP(O)(=S)OC[C@H]3O[C@H](CC3OP(O)(=S)OC[C@@]34COC([C@@H](O3)N3C=CC(N)=NC3=O)C4OP(O)(=S)OC[C@]34COC(C3O)[C@@H](O4)N3C=CC(N)=NC3=O)N3C=C(C)C(=O)NC3=O)N3C=NC4=C3N=CN=C4N)N3C=NC4=C3N=CN=C4N)N3C=CC(N)=NC3=O)N3C=C(C)C(=O)NC3=O)[C@@H](COP(O)(=S)OC3C4OC[C@]3(COP(O)(=S)OC3C[C@@H](O[C@@H]3COP(O)(=S)OC3C5OC[C@]3(CO)O[C@H]5N3C=CC(N)=NC3=O)N3C=CC(N)=NC3=O)O[C@H]4N3C=NC4=C3N=CN=C4N)O2)C(=O)NC1=O

Miravirsen (INN; codenamed SPC3649) is an experimental drug for the treatment of hepatitis C, being developed by Santaris Pharma. As of 2017 it was in Phase II clinical trials. [1]

Miravirsen had been given by subcutaneous injection in early clinical trials as of 2017. [1] It is antisense to a human microRNA called miR-122. miR-122 ferries an argonaute protein to 5'-UTR region of viral RNA, where it binds, protecting the RNA from being destroyed by normally present nucleases; by binding to miR-122, miravirsen removes that protection and the virus RNA can be destroyed. [1] There is some evidence that the 5'-UTR region mutates under repeated exposure to miravirsen. [1]

Chemistry

Miravirsen is a modified antisense oligonucleotide consisting of a chain of 15 nucleotides, the base sequence of which is designed to selectively bind to miR-122. [1] [2] Seven of the 15 sugar units are deoxyriboses, and the other eight are riboses with an additional bridge between the 2' oxygen and the 4' carbon atoms; this makes miravirsen a locked nucleic acid gapmer. Furthermore, miravirsen uses phosphorothioate linkages instead of the phosphate linkages in natural oligonucleotides to make it stable towards degradation by nucleases. [2]

The complete base sequence is

mC*-dC-A*-dT-dT-G*-mU*-dC-dA-mC*-dA-mC*-dT-mC*-mC* [d = 2'-deoxy, m = 5-methyl, * = 2'-O,4'-C-methylene, i.e. bridged or "locked" sugar]

with 3'→5' phosphorothioate linkages. [2]

References

  1. 1 2 3 4 5 Titze-de-Almeida R, David C, Titze-de-Almeida SS (July 2017). "The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market". Pharmaceutical Research. 34 (7): 1339–1363. doi:10.1007/s11095-017-2134-2. PMID   28389707. S2CID   4925216.
  2. 1 2 3 "Miravirsen". PubChem .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.